Precigen, Inc., formerly known as Intrexon Corporation, is a biopharmaceutical company focused on advancing next-generation gene and cell therapies. The company's research and development efforts are centered on immuno-oncology, autoimmune disorders, and infectious diseases. Precigen leverages proprietary therapeutic platforms, including its AdenoVerse technology for adenoviral vector-based gene delivery and its UltraCAR-T platform for chimeric antigen receptor T-cell therapies. In August 2025, the company achieved a major milestone with the FDA approval of PAPZIMEOS, an immunotherapy for adult recurrent respiratory papillomatosis (RRP), marking its transition to a commercial-stage entity. Headquartered in Germantown, Maryland, Precigen manages a pipeline of preclinical and clinical assets aimed at addressing high unmet medical needs.
